Melatonin Modulates the
Action of Near Infrared Radiation on Cell Adhesion
(Cervical Cancer-April 29, 2003)
According to published
research from Russia, "The adhesion of human cervical cancer (HeLa) cells to
a glass matrix is evaluated following their
irradiation in a suspension with a pulsed near-infrared (IR) light-emitting
diode (wavelength 820 nm, pulse repetition frequency 10 Hz, irradiation dose
16-120 J/m2 ) when melatonin (4 x 10-11 to 4 x 10-5
m) is added to cell suspension immediately before or after the irradiation.
"Also, the dependence of
visible-to-near-IR radiation (600-840 nm, 52 J/m2) on cell
adhesion (action spectrum) is recorded in absence and presence of melatonin
(4 x 10-6 m). It is found that melatonin in pharmacological
concentrations (but not in physiological range) inhibited cell adherence,"
wrote T.I. Karu and colleagues, Russian Academy of Science, Institute of
Laser & Information Technology.
"Irradiation of cells before
or after melatonin treatment normalizes cell adhesion to control level.
Melatonin in pharmacological concentrations eliminates stimulation of cell
attachment induced by irradiation. Pretreatment (but not post-treatment)
with melatonin in the physiological concentration eliminates cell adhesion
stimulation induced by irradiation," the researchers stated.
The researchers concluded:
"Melatonin modifies the light action spectrum significantly in near IR
region (760-840 nm only). Thus, the peak at 820 - 830 nm characteristic for
the light action spectrum is fully reduced."
Karu and colleagues published
their findings in the Journal of Pineal Research (Melatonin modulates
the action of near infrared radiation on cell adhesion. J Pineal Res,
2003;34(3):167-172).
Additional information can be
obtained by contacting T.I. Karu, Russian Academy of Science, Institute of
Laser & Information Technology, Pionerskaya Str 2, Troitsk 142190, Moscow
Region, Russia.
The information in this
article comes under the major subject area of Oncology. This article was
prepared by Cancer Weekly editors from staff and other reports.
©Copyright 2003, Cancer
Weekly via NewsRx.com & NewsRx.net
This story has been adapted from a news
release issued by NewsRx.com & NewsRx.net